RECRUITING · INTERVENTIONAL · TREATMENT study · Diabetes Mellitus, Type 1 · Phase 3 · Enrollment 60 · Sponsor: University of Colorado, Denver
Official title: Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Summary: This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.
Conditions: Diabetes Mellitus, Type 1
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE3
Enrollment: 60 (ESTIMATED)
Status: RECRUITING
Completion: 2027-12-01 (ESTIMATED)